| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
RxSight, Inc. Common Stock$6.01
-0.07 (-1.15%)
F 16Pipeline Score MedTech · Commercial
Market Cap
281.85 M
EPS
-0.95
P/E Ratio
-7.16 $
Value Trade
5.90 M
SEC Financials
Q4 2025Dilution Risk
Revenue
32.61 M
R&D Expenses
8.90 M
Operating CF
-3.88 M
Total Assets
311.81 M
Total Liabilities
36.13 M
Equity
275.68 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
228.13 M
Monthly Burn
1.29 M
Runway
175.9 mo
Burn Trend
SEC Filing
Feb 25, 2026
Overview
Volume
540.87 K
52 Week Range
5.90 - 16.74
% held by Insiders
7.12 %
% held by Institutions
91.71 %
Enterprise Value
64.76 M
Total Shares
41.10 M
Short %
10.16 %
Float Shares
37.81 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F16
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 13%
Micro Cap (rank 805 of 924)
Percentile RankRxSight, Inc. Common Stock has significant pipeline risk (16/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RXST
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RXST Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-RXST
Jul 26, 2026▲ +8.7%on this news
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight, Inc. has granted inducement stock options and restricted stock units to Aziz Mottiwala, the new President and CEO, as part of his employment agreement. The stock options cover 571,286 shares with an exercise price of $5.19, while the RSUs cover 2,312,138 shares. The vesting schedule is structured over a three-year period, aligning with Nasdaq Listing Rule 5635(c)(4).
Read more →-RXST
Jul 15, 2026▲ +6.1%on this news
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
RxSight, Inc. has announced the appointment of Aziz Mottiwala as the new CEO, effective July 20, 2026, succeeding Ron Kurtz, M.D., who will remain as Chief Medical Officer. Mottiwala has a strong background in commercial leadership within the eye care sector. The transition aims to leverage his expertise to enhance RxSight's innovative adjustability technology in cataract surgery.
Read more →-RXST
Jul 6, 2026Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Alcon and RxSight have announced a collaboration aimed at developing adjustable posterior chamber intraocular lenses (PCIOLs). This partnership is expected to leverage both companies' expertise in ophthalmic technologies. Details regarding the timeline and specific goals of the collaboration have not been disclosed.
Read more →-RXST
Jul 6, 2026RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
RxSight, Inc. has announced preliminary financial results for Q2 2026, projecting revenues between $32 to $34 million, including $5 to $7 million from a collaboration with Alcon. The company is advancing its product pipeline with next-generation light-adjustable lenses, despite facing competitive challenges. RxSight maintains a strong cash position of approximately $209 million.
Read more →-RXST
Jun 1, 2026Astigmatism After Cataract Surgery: What It Means and Your Options for Correction
The article discusses the occurrence of astigmatism after cataract surgery, which can lead to blurry or doubled vision. It highlights that astigmatism is more common than patients might think and can arise even when surgery is successful. The piece emphasizes the importance of addressing this condition and exploring correction options.
Read more →-RXST
May 19, 2026RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
RxSight, Inc. will present at the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026. Management will participate in a fireside chat at 10:00 a.m. Pacific Time. The event will be accessible via a live and archived webcast on the company's investor relations website.
Read more →-RXST
May 6, 2026▼ -6.6%on this news· ran to -21% by day 3
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
RxSight, Inc. reported Q1 2026 sales of $30.9 million, an 18.5% decline year-over-year. The company highlighted robust clinical data from the ASCRS meeting and received regulatory approval in New Zealand. Despite the decrease in sales and an increased net loss, RxSight maintained its full-year sales outlook and gross margin guidance.
Read more →-RXST
Apr 29, 2026▼ -5%on this news
RxSight, Inc. to Present at the Bank of America Healthcare Conference
RxSight, Inc. has announced its participation in the Bank of America Healthcare Conference, scheduled for May 13, 2026. The management will engage in a fireside chat, highlighting the company's innovative ophthalmic medical devices. The event will be accessible via a live and archived webcast on their investor relations website.
Read more →-RXST
Apr 22, 2026RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
RxSight, Inc. will announce its first-quarter financial results on May 6, 2026, after market close. The management will hold a conference call at 1:30 p.m. PT to discuss these results. Participants can join the call via phone or listen online. The company focuses on advanced ophthalmic devices for cataract surgery.
Read more →-RXST
Apr 3, 2026▲ +5.7%on this news
RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
RxSight, Inc. has announced its participation in the 25th Annual Needham Virtual Healthcare Conference. Management will engage in a fireside chat scheduled for April 16, 2026, at 8:00 a.m. Pacific Time. The event will be accessible via a live and archived webcast on the company's investor relations website.
Read more →-RXST
Feb 26, 2026▼ -10.1%on this news
RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance
RxSight, Inc. reported its financial results for Q4 and the full year 2025, highlighting a 4% decrease in global sales to $134.5 million. While LAL revenue grew by 12%, this was overshadowed by a 48% decline in LDD system sales. The company also announced a net loss of $(38.9) million for the year, with a focus on expanding its commercial initiatives and international presence.
Read more →-RXST
Jan 11, 2026▲ +14.1%on this news
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer Aliso Viejo, Calif. (Nasdaq: RXST) –
RxSight, Inc. has announced preliminary unaudited financial results for Q4 and the full year 2025, indicating an increase in revenue and procedure volume. The company has appointed Mark Wilterding as the new Chief Financial Officer, expected to enhance financial operations moving forward. Despite positive indicators, results remain preliminary and are subject to an audit, suggesting some uncertainty in the reported figures. RxSight continues to strengthen its position in the cataract surgery market with growing adoption of its adjustable intraocular lens technology.
Read more →-RXST
Dec 22, 2025RXSIGHT, INC. ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION Aliso Viejo, Calif. (Nasdaq: RXST)
RxSight, Inc. has announced that Shelley Thunen, the Chief Financial Officer, will transition from her role while continuing to support the company as a consultant. Thunen has been instrumental in RxSight's growth, guiding the company through pivotal financial milestones including its IPO in 2021. The leadership recognized her significant contributions in developing the company's financial strategy and achieving over 1,100 Light Delivery Devices in the field and a quarter million procedures performed. A successor will be appointed before her departure on January 31, 2026.
Read more →-RXST
Nov 5, 2025▼ -7.3%on this news
RXSIGHT, INC. REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS Aliso Viejo, Calif. (Nasdaq: RXST) –
RxSight, Inc. reported its financial results for the third quarter of 2025, revealing a 14% decrease in revenue to $30.3 million compared to the same period in 2024. The company experienced a 6% increase in the sale of Light Adjustable Lenses (LAL) but faced a significant decline in sales of Light Delivery Devices (LDD), which dropped by 68%. Despite the challenges, RxSight improved its gross margin to 80% and has narrowed its revenue guidance for the full year 2025, suggesting a strategic focus on profitability and operational efficiency. The company continues to invest in its commercial infrastructure and aims to stabilize the procedures in its market segment.
Read more →-RXST
Aug 7, 2025RXSIGHT, INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Aliso Viejo, Calif. (Nasdaq: RXST) –
RxSight, Inc. reported its financial results for the second quarter of 2025, revealing total revenues of $33.6 million, a decrease of 4% from the prior year. Despite a 13% increase in revenue from Light Adjustable Lenses, sales of Light Delivery Devices saw a significant decline of 49%. The company received FDA approval for expanding its product range and launched the RxSight system in South Korea, aiming for strategic growth. Net loss in Q2 2025 rose to $(11.8) million, up from $(6.1) million in Q2 2024.
Read more →-RXST
Aug 4, 2025RXSIGHT, INC. APPOINTS RAYMOND W. COHEN TO ITS BOARD OF DIRECTORS Aliso Viejo, Calif., (Nasdaq: RXST)
RxSight, Inc. has appointed Raymond W. Cohen to its Board of Directors, a move expected to enhance the company's growth and strategy in the ophthalmic medical device market. Cohen brings over four decades of experience in medical technology, previously co-founding Axonics, Inc. which achieved substantial revenue growth. He expressed confidence in RxSight's potential to expand its reach within the premium intraocular lens market, leveraging its unique Light Adjustable Lens system. This appointment reflects RxSight's commitment to providing customized vision solutions for cataract surgery patients.
Read more →-RXST
Jul 8, 2025RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. has announced preliminary financial results for the second quarter of 2025, revealing an expected revenue of approximately $33.6 million. This marks a 4% decrease from the corresponding period last year and an 11% decline from the first quarter of 2025, largely due to reduced sales of Light Delivery Devices. The company also issued revised full-year guidance, adjusting its revenue expectations downwards by nearly 14% to 7%. Notably, the gross margin guidance has been improved, suggesting potential for better financial performance despite other setbacks.
Read more →-RXST
May 7, 2025▲ +6.8%on this news
RXSIGHT, INC. REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. reported its financial results for the first quarter of 2025, showing significant revenue growth of 28% to $37.9 million compared to the same quarter in the prior year. This growth was driven by a marked increase in sales of Light Adjustable Lenses and Light Delivery Devices. While the company is expanding its operations and investing in product development, it still reported a net loss of $(8.2) million, reflecting ongoing costs associated with scaling its business. Overall, RxSight reiterated its positive outlook for the full year 2025.
Read more →-RXST
Apr 2, 2025RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. has reported preliminary revenue results for the first quarter of 2025, indicating an expected revenue of approximately $37.9 million, which shows a year-over-year growth of 28%. However, the company has revised its full-year revenue guidance downward, now projecting revenues between $160.0 million and $175.0 million. Increased sales of its Light Adjustable Lenses and expansion of its installed base of Light Delivery Devices were highlights, although the adjusted guidance reflects challenges in the premium IOL market and economy. A conference call is scheduled for April 3, 2025, to discuss these preliminary results and guidance updates further.
Read more →-RXST
Feb 25, 2025RXSIGHT, INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS, REAFFIRMS 2025 GUIDANCE Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. announced its financial results for Q4 and full-year 2024, reporting a revenue increase of 41% in Q4 compared to the same quarter last year. The company sold 29,069 Light Adjustable Lenses, marking a significant rise in procedure volumes. However, despite strong revenue growth, RxSight incurred a net loss of $(5.9) million in Q4. The company has reaffirmed its revenue guidance for 2025, projecting further growth in earnings and expansion in the global market.
Read more →-RXST
Jan 12, 2025▼ -8.1%on this news
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. reported preliminary unaudited financial results for Q4 and full-year 2024, projecting significant growth, with Q4 revenues expected to reach $40.2 million, a 41% increase year-over-year. For 2024, the total revenue is anticipated to be around $139.9 million, marking a 57% rise compared to the previous year, driven by strong sales of Light Adjustable Lenses and Light Delivery Devices. The company also provided guidance for 2025, expecting revenue between $185 million and $197 million. The preliminary figures are subject to audit, and the final results are expected to be announced in February 2025.
Read more →-RXST
Nov 7, 2024▼ -7.1%on this news
RXSIGHT, INC. REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. reported its financial results for the third quarter of 2024, highlighting a revenue increase of 59% to $35.3 million compared to the previous year. The strong performance was driven by high sales of Light Adjustable Lenses and Light Delivery Devices. However, the company still reported a net loss of $(6.3) million and an increase in operating expenses, reflecting ongoing financial pressures despite the overall growth. The company has revised its full-year revenue guidance to the upper end of its previous range, indicating positive expectations moving forward.
Read more →-RXST
Aug 5, 2024RXSIGHT, INC. REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. reported its financial results for the second quarter of 2024, highlighting a 68% increase in revenue to $34.9 million compared to the same quarter in 2023. The growth was primarily driven by a significant rise in the sale of Light Adjustable Lenses and Light Delivery Devices. Despite reporting a net loss, the company’s losses showed an improvement compared to the prior year. Additionally, RxSight raised its full-year revenue guidance, reflecting positive performance and market trends.
Read more →-RXST
May 8, 2024RxSight, Inc. Announces Pricing of Public Offering of Common Stock Aliso Viejo, Calif. (NASDAQ: RXST)
RxSight, Inc. has announced the pricing of its public offering of common stock, aiming to sell 1,785,714 shares at a price of $56.00 each, which could generate approximately $100 million in gross proceeds. The company will use the net proceeds for commercial and marketing expansion, including international growth, as well as funding product and clinical development. The offering is expected to close on or about May 13, 2024, subject to customary closing conditions.
Read more →-RXST
May 6, 2024RXSIGHT, INC. REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. reported strong financial results for the first quarter of 2024, with a 69% increase in revenue to $29.5 million, driven largely by an increase in sales of its Light Adjustable Lens (LAL) technology. The company noted a 92% rise in LAL procedure volume and an 18% growth in Light Delivery Device sales. Despite these positive trends, RxSight recorded a net loss of $(9.1) million, although this represents an improvement from the previous year's loss. The company has increased its revenue and gross margin guidance for the year ahead, reflecting continued confidence in its product offerings.
Read more →-RXST
Feb 28, 2024RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. has reported impressive financial results for Q4 2023 and the full year, with a notable 78% increase in quarterly revenue to $28.6 million. This growth is attributed to the sale of 77 Light Delivery Devices and a remarkable 98% increase in the volume of Light Adjustable Lens procedures. Despite the growth, the company continued to incur losses, reporting a $9.2 million net loss for the quarter. Looking ahead, RxSight is optimistic about its revenue guidance for 2024, projecting significant increases compared to 2023 performance.
Read more →-RXST
Jan 7, 2024▲ +22.8%on this news
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. announced preliminary unaudited financial results for Q4 and full-year 2023, indicating strong revenue growth. For Q4 2023, revenue is expected to reach approximately $28.6 million, marking a 78% increase year-over-year, while full-year revenue is projected at around $89.1 million, an 82% increase. The company anticipates continued growth into 2024, forecasting revenue between $128 million and $135 million. Full audited results are expected in February 2024.
Read more →-RXST
Nov 9, 2023RxSight, Inc. Reports Third Quarter 2023 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. announced its third quarter 2023 financial results, showcasing a 76% increase in revenue year-over-year, totaling $22.2 million. The growth was driven by a 107% jump in Light Adjustable Lens (LAL) procedures and a 35% increase in Light Delivery Device (LDD) sales. Despite these gains, the company reported a net loss of $12.4 million, although this was an improvement over the same quarter in 2022. Additionally, RxSight raised its 2023 revenue guidance to between $85 million and $87 million as part of its financial expectations for the year.
Read more →-RXST
Aug 7, 2023RxSight, Inc. Reports Second Quarter 2023 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. reported its financial results for the second quarter of 2023, revealing an 83% increase in revenue year-over-year, amounting to $20.8 million. This growth was driven by a notable rise in the sales of its Light Adjustable Lenses and Light Delivery Devices. The company increased its guidance for the full year, highlighting strong demand and positioning in the premium cataract market. Despite the positive revenue growth, RxSight also faced a net loss and rising operating expenses.
Read more →-RXST
May 9, 2023RxSight, Inc. Reports First Quarter 2023 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. reported a significant revenue increase of 96% for the first quarter of 2023, totaling $17.5 million. This growth was driven by a notable rise in sales of their Light Adjustable Lens and Delivery Device, alongside an improved gross profit margin. While the company experienced a net loss of $13.2 million, this was an improvement from the previous year's loss of $17.6 million. For the year, RxSight has updated its revenue guidance to a projected growth of 61% to 71% compared to the previous year.
Read more →-RXST
Mar 6, 2023▲ +13%on this news
RxSight, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. announced strong financial results for the fourth quarter and full year of 2022, with revenues rising 91% in Q4 compared to the previous year. The sale of Light Delivery Devices and Light Adjustable Lenses saw significant increases, driving overall revenue growth. Despite the positive revenue increases, the company reported continued net losses, highlighting growing operational expenses. Moving forward, RxSight has provided a positive outlook for 2023, anticipating robust revenue growth.
Read more →-RXST
Jan 8, 2023RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial and Operational Results Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. has announced preliminary unaudited financial results for the fourth quarter and full year of 2022. The company expects a revenue increase of approximately 91% for the fourth quarter and 117% for the full year compared to the prior year, driven by sales of Light Delivery Devices and Light Adjustable Lenses. The results indicate growing awareness and demand for their products in the cataract surgery space. However, all financial figures are preliminary and may change upon completion of the audit process.
Read more →-RXST
Nov 7, 2022▲ +7.9%on this news
RxSight, Inc. Reports Third Quarter 2022 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. Reports Third Quarter 2022 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) November 7, 2022 RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the t
Read more →-RXST
Aug 8, 2022RxSight, Inc. Reports Second Quarter 2022 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. Reports Second Quarter 2022 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) August 8, 2022 RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the th
Read more →-RXST
Aug 8, 2022RxSight, Inc. Files Shelf Registration Statement and Announces $50 Million At-The-Market Equity Offering Program Aliso Viejo, Calif. (NASDAQ: RXST)
RxSight, Inc. Files Shelf Registration Statement and Announces $50 Million At-The-Market Equity Offering Program Aliso Viejo, Calif. (NASDAQ: RXST) August 8, 2022 RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following catarac
Read more →-RXST
May 5, 2022▼ -10.5%on this news
RxSight, Inc. Reports First Quarter 2022 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. Reports First Quarter 2022 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) May 5, 2022 RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three
Read more →-RXST
Mar 8, 2022▼ -8.7%on this news
RxSight, Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight, Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) March 8, 2022 RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial res
Read more →-RXST
Jan 9, 2022▲ +28.2%on this news
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial and Operational Results Aliso Viejo, Calif.
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial and Operational Results Aliso Viejo, Calif., January 9, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of pati
Read more →-RXST
Jan 4, 2022▼ -11.2%on this news
RxSight, Inc. Appoints Dr. Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors Aliso Viejo, Calif., (NASDAQ: RXST)
RxSight, Inc. Appoints Dr. Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors Aliso Viejo, Calif., (NASDAQ: RXST) January 4, 2022 RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery,
Read more →-RXST
Nov 10, 2021RxSight Reports Third Quarter 2021 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight Reports Third Quarter 2021 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) November 10, 2021 RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three
Read more →-RXST
Sep 9, 2021RxSight Reports Second Quarter 2021 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) –
RxSight Reports Second Quarter 2021 Financial Results Aliso Viejo, Calif. (NASDAQ: RXST) September 9, 2021 RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three
Read more →Competitive Position
How RXST ranks across every disease it competes inCompetitive Position is a premium feature
See how RXST ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial